Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icatibant for sweating-induced dermal pain
jRCTs061210021Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, single-blind trial of icatibant in Cholinergic Urticaria (CU) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in VAS score of dermal pain induced by heat stimuli. Started Dec 2021; status: completed.
02
Drugs
icatibant
03
Conditions
Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on jRCTs061210021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210021.